Artivion
AORTAORT · Stock Price
Historical price data
Overview
Artivion (NYSE: AORT) is a specialized medical device innovator with a mission to deliver breakthrough technologies for aortic disease. The company has built a synergistic portfolio through strategic acquisitions like On-X and Ascyrus Medical, achieving significant milestones including recent FDA HDE approval for its flagship AMDS device. Its strategy centers on dominating the high-complexity aortic surgery market with a combination of biological tissues, advanced prosthetics, and novel hybrid stent-graft systems.
Technology Platform
An integrated platform combining proprietary cryopreserved biological tissues (allografts, xenografts), advanced prosthetic heart valve engineering (pyrolytic carbon), and novel hybrid aortic arch stent-graft technologies for complex aortic and cardiac reconstructions.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Aortic Valve Disease | Phase 3 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Artivion competes with diversified giants like Medtronic and Edwards Lifesciences, as well as specialized players. Its key advantages are its singular aortic focus, which drives deep clinical relationships, and its unique integrated portfolio of biological tissues, mechanical valves, and hybrid stent-grafts, allowing it to serve as a comprehensive partner for complex surgeries.